Monday - April 28, 2025

LOGIN  |  REGISTER
Chimerix
Chimerix

Apollo Medical Holdings Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

December 18, 2023 | Last Trade: US$30.60 0.80 -2.55

ALHAMBRA, Calif., Dec. 18, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that effective on December 15, 2023, the Compensation Committee of ApolloMed's Board of Directors (the "Committee") granted a total of 38,779 shares of restricted common stock to eight newly-hired non-executive employees, under the Apollo Medical Holdings, Inc. Employment Inducement Award Plan (the "Inducement Plan"). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of the Company (or following a bona fide period of non-employment) as an inducement material to such individuals' commencement of employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Of the restricted stock granted, 22,182 shares will vest, subject to continued employment, over four years in substantially equal annual installments on the first, second, third and fourth anniversaries of the grant date, and 16,597 shares will vest, subject to continued employment, based on the achievement of the applicable performance targets and the same time-based vesting conditions as the other shares of restricted stock granted. The restricted stock is subject to the terms and conditions of the Inducement Plan and an award agreement covering each grant.

About Apollo Medical Holdings, Inc.

ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver outcomes-based medical care to patients in a cost-effective manner.

Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models. For more information, please visit www.apollomed.net.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations
(626) 943-6491
investors@apollomed.net

Asher Dewhurst, ICR Westwicke
ApolloMedIR@westwicke.com

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page